ArticleScience advances2021
Persistent repression of tau in the brain using engineered zinc finger protein transcription factors.
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
6.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 74 citations in OpenAlex.
- Zinc Fingers as Programmable Metalloprotein Scaffolds for Altering Pathogenic Biomolecular Phase Transitions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Tau dysfunction in alzheimer's disease: molecular and cellular mechanisms, genetic modulation, and therapeutic perspectives.Molecular biology reports · 2026Review
- Artificial microRNAs targeting tau enable post-symptomatic functional recovery in aged tauopathy mice.Molecular therapy. Nucleic acids · 2026Article
- Epigenetic editing: from concept to clinic.Nature reviews. Drug discovery · 2026Review
- Epigenome editing based treatment: Progresses and challenges.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Review
- AAV-mediated gene therapy for Alzheimer's disease: neuroprotective mechanisms and translational challenges.Frontiers in aging neuroscience · 2026Review
- Common and rare variant analyses implicateNPJ dementia · 2026Article
- Genetic therapies for neurological diseases.Pharmacological reviews · 2026Review
- AAV delivery of artificial miRNA targeting MAPT for the reduction of tau pathology in Alzheimer's disease.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- A manifesto for Alzheimer's disease drug discovery in the era of disease-modifying therapies.Molecular neurodegeneration · 2025Review
- Epigenome Engineering Using dCas Systems for Biomedical Applications and Biotechnology: Current Achievements, Opportunities and Challenges.International journal of molecular sciences · 2025Review
- Enhanced anti-tumor activity by zinc finger repressor-driven epigenetic silencing of immune checkpoints and TGFBR2 in CAR-T cells and TILs.Molecular therapy. Oncology · 2025Article
- Article
- Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: Proceedings of the Tau2024 Global Conference.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Hierarchical metabolic engineering for rewiring cellular metabolism.FEMS microbiology reviews · 2025Review
- PROTAC technology for prostate cancer treatment.Acta materia medica · 2025Article
- Aging and Alzheimer's: the critical role of mitochondrial dysfunction and synaptic alterations.Frontiers in synaptic neuroscience · 2025Review
- Development of artificial transcription factors and their applications in cell reprograming, genetic screen, and disease treatment.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Review
- Precision epigenetic editing: Technological advances, enduring challenges, and therapeutic applications.Cell chemical biology · 2024Review
- Gene therapy for CNS disorders: modalities, delivery and translational challenges.Nature reviews. Neuroscience · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 3 institutions in 2 countries.
Susanne WegmannMassachusetts General Hospital, Massachusetts Institute of Neurodegenerative Disease, Charlestown, MA 02129, USA. bzeitler@sangamo.com susanne.wegmann@dzne.de bhyman@mgh.harvard.edu.ORCID 0000-0002-5388-2479
Sarah L DeVosMassachusetts General Hospital, Massachusetts Institute of Neurodegenerative Disease, Charlestown, MA 02129, USA.ORCID 0000-0003-0921-1763
Bryan ZeitlerSangamo Therapeutics Inc., Richmond, CA 94804, USA. bzeitler@sangamo.com susanne.wegmann@dzne.de bhyman@mgh.harvard.edu.ORCID 0000-0002-4439-0085
Kimberly MarlenSangamo Therapeutics Inc., Richmond, CA 94804, USA.ORCID 0000-0001-6883-9484
Rachel E BennettMassachusetts General Hospital, Massachusetts Institute of Neurodegenerative Disease, Charlestown, MA 02129, USA.ORCID 0000-0001-9640-0575
Marta Perez-RandoMassachusetts General Hospital, Massachusetts Institute of Neurodegenerative Disease, Charlestown, MA 02129, USA.ORCID 0000-0002-5286-1545
Danny MacKenzieMassachusetts General Hospital, Massachusetts Institute of Neurodegenerative Disease, Charlestown, MA 02129, USA.ORCID 0000-0002-3632-6040
Qi YuSangamo Therapeutics Inc., Richmond, CA 94804, USA.
Caitlin ComminsMassachusetts General Hospital, Massachusetts Institute of Neurodegenerative Disease, Charlestown, MA 02129, USA.
Riley N BannonMassachusetts General Hospital, Massachusetts Institute of Neurodegenerative Disease, Charlestown, MA 02129, USA.
Bianca T CorjucMassachusetts General Hospital, Massachusetts Institute of Neurodegenerative Disease, Charlestown, MA 02129, USA.ORCID 0000-0002-2358-2539
Alison ChaseMassachusetts General Hospital, Massachusetts Institute of Neurodegenerative Disease, Charlestown, MA 02129, USA.ORCID 0000-0003-4543-2395
Lisa DiezGerman Center for Neurodegenerative Diseases (DZNE), 10117 Berlin, Germany.ORCID 0000-0003-3101-0191
Hoang-Oanh B NguyenSangamo Therapeutics Inc., Richmond, CA 94804, USA.
Sarah HinkleySangamo Therapeutics Inc., Richmond, CA 94804, USA.ORCID 0000-0001-6245-0013
Lei ZhangSangamo Therapeutics Inc., Richmond, CA 94804, USA.ORCID 0000-0003-4133-3066
Alicia GoodwinSangamo Therapeutics Inc., Richmond, CA 94804, USA.
Annemarie LedeboerSangamo Therapeutics Inc., Richmond, CA 94804, USA.
Stephen LamSangamo Therapeutics Inc., Richmond, CA 94804, USA.ORCID 0000-0002-2559-4998
Irina AnkoudinovaSangamo Therapeutics Inc., Richmond, CA 94804, USA.
Hung TranSangamo Therapeutics Inc., Richmond, CA 94804, USA.
Nicholas ScarlottSangamo Therapeutics Inc., Richmond, CA 94804, USA.ORCID 0000-0003-2827-6909
Rainier AmoraSangamo Therapeutics Inc., Richmond, CA 94804, USA.ORCID 0000-0001-8580-1859
Richard SuroskySangamo Therapeutics Inc., Richmond, CA 94804, USA.ORCID 0000-0002-0563-9466
Jeffrey C MillerSangamo Therapeutics Inc., Richmond, CA 94804, USA.
Ashley B RobbinsMassachusetts General Hospital, Massachusetts Institute of Neurodegenerative Disease, Charlestown, MA 02129, USA.ORCID 0000-0002-6675-1603
Edward J RebarSangamo Therapeutics Inc., Richmond, CA 94804, USA.
Fyodor D UrnovSangamo Therapeutics Inc., Richmond, CA 94804, USA.ORCID 0000-0001-7542-4084
Michael C HolmesSangamo Therapeutics Inc., Richmond, CA 94804, USA.ORCID 0000-0002-6697-4225
Amy M PoolerSangamo Therapeutics Inc., Richmond, CA 94804, USA.
Brigit RileySangamo Therapeutics Inc., Richmond, CA 94804, USA.
H Steve ZhangSangamo Therapeutics Inc., Richmond, CA 94804, USA.
Bradley T HymanMassachusetts General Hospital, Massachusetts Institute of Neurodegenerative Disease, Charlestown, MA 02129, USA. bzeitler@sangamo.com susanne.wegmann@dzne.de bhyman@mgh.harvard.edu.ORCID 0000-0002-7959-9401
Sangamo BioSciences (United States) · USMassachusetts General Hospital · USGerman Center for Neurodegenerative Diseases · DE
Funding
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI STEVEN E ARNOLD · 2019 to 2026
$36.5MTraining in the Molecular Biology of Neurodegeneration and Alzheimer's DiseaseT32AG000222 · NIA · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Bruce A YANKNER · 1992 to 2026
$18.5MTraining Program in Computational GenomicsT32HG000046 · NHGRI · UNIVERSITY OF PENNSYLVANIA · PI JUNHYONG KIM, Mingyao Li · 1999 to 2026
$9.5MAre multiple tau species toxic in Alzheimer's Disease?RF1AG059789 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HYMAN, BRADLEY T. · 2018 to 2018
$2.7MNHGRI NIH HHS T32 HG000046NIA NIH HHS P30 AG062421NIA NIH HHS RF1 AG059789NIA NIH HHS T32 AG000222
Abstract
Neuronal tau reduction confers resilience against β-amyloid and tau-related neurotoxicity in vitro and in vivo. Here, we introduce a novel translational approach to lower expression of the tau gene
Indexed as
Alzheimer DiseaseTranscription FactorsAmyloid beta-PeptidesAnimalsBrainDependovirusDisease Models, AnimalMicePlaque, Amyloidtau ProteinsZinc FingersAmyloid beta-Peptidestau ProteinsTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.